Regeneron Pharmaceuticals, Inc. reported financial results for the third quarter of 2026, with total revenues increasing 36% year-over-year to $5.12 billion. The company reported GAAP net income of $1.95 billion, or $18.45 per share, and non-GAAP net income of $2.15 billion, or $20.07 per share.
Key product performance included record net sales for Dupixent, which increased 35% to $6.5 billion globally. EYLEA HD U.S. net sales rose 62% to $699 million, while Libtayo global net sales increased 51% to $550 million. The company noted that EYLEA U.S. net sales decreased 41% to $400 million due to competitive pressures and patient transitions to EYLEA HD.
In other business developments, Regeneron expanded its collaboration with Sanofi to include multiple next-generation, long-acting immunology antibodies. Under the amended agreement, the company received an up-front payment of $1.0 billion, with potential future milestone payments of up to an additional $7.0 billion. The company also received FDA approval for Pasatru (garetosmab) to treat fibrodysplasia ossificans progressiva (FOP).
Regarding capital allocation, Regeneron repurchased $2.3 billion of its common stock during the nine months ended September 30, 2026. In October 2026, the company declared a cash dividend of $0.94 per share, payable on December 3, 2026.
